CEACAM1
CEA Cell Adhesion Molecule 1
Also known as: CD66a, BGP
Immune checkpoint molecule whose upregulation predicts sepsis onset in trauma patients.
Biological Function
CEACAM1 is an immunoregulatory glycoprotein expressed on neutrophils, T-cells, and epithelial cells. It functions as an immune checkpoint, suppressing T-cell activation and NK cell cytotoxicity. In the context of sepsis, CEACAM1 upregulation on neutrophils marks the transition from controlled immune response to pathological immune suppression — a hallmark of sepsis-induced immunoparalysis.
Why Biomeme Monitors This Target
CEACAM1 is one of the most promising transcriptomic biomarkers for early sepsis prediction. Research has shown that CEACAM1 mRNA upregulation in peripheral blood can precede clinical sepsis symptoms by 24-48 hours. For Biomeme's host response application, CEACAM1 is a cornerstone target in the sepsis early warning gene signature.
Expression Context
Low baseline expression on resting immune cells. Rapidly upregulated during the immune response to infection. Persistent elevation indicates immune exhaustion and predicts poor sepsis outcomes. Returns to baseline during recovery.
Signaling Pathway
Quick Facts
- Symbol
- CEACAM1
- Category
- Sepsis & Host Response
- Applications
- Sepsis, Host Response
- Linked Therapies
- 0
References
Related Targets
Monitor CEACAM1 Expression.
Biomeme's multiplexed platform can include CEACAM1 in a custom panel alongside up to 47 other molecular targets — in a single rapid run.
Discuss Your Panel